Continuing Immune Checkpoint Inhibitors as a Second-Line Treatment in Patients With Extensive-Stage SCLC Who Progressed on Chemoimmunotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: